[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MX2021006241A - Vectores para la fabricacion de proteinas. - Google Patents

Vectores para la fabricacion de proteinas.

Info

Publication number
MX2021006241A
MX2021006241A MX2021006241A MX2021006241A MX2021006241A MX 2021006241 A MX2021006241 A MX 2021006241A MX 2021006241 A MX2021006241 A MX 2021006241A MX 2021006241 A MX2021006241 A MX 2021006241A MX 2021006241 A MX2021006241 A MX 2021006241A
Authority
MX
Mexico
Prior art keywords
vectors
protein
protein manufacture
manufacture
interest
Prior art date
Application number
MX2021006241A
Other languages
English (en)
Inventor
Gregory T Bleck
Rachel H Kravitz
Chad A Hall
Original Assignee
Catalent Pharma Solutions Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Catalent Pharma Solutions Llc filed Critical Catalent Pharma Solutions Llc
Publication of MX2021006241A publication Critical patent/MX2021006241A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/10041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/10043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a vectores y su uso para desarrollar líneas de células hospedadoras para la producción de una proteína de interés y, en particular, a vectores que utilizan un promotor débil para impulsar un marcador seleccionable.
MX2021006241A 2018-12-04 2019-12-04 Vectores para la fabricacion de proteinas. MX2021006241A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862775194P 2018-12-04 2018-12-04
PCT/US2019/064423 WO2020117910A1 (en) 2018-12-04 2019-12-04 Vectors for protein manufacture

Publications (1)

Publication Number Publication Date
MX2021006241A true MX2021006241A (es) 2021-08-11

Family

ID=70974897

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021006241A MX2021006241A (es) 2018-12-04 2019-12-04 Vectores para la fabricacion de proteinas.

Country Status (11)

Country Link
US (1) US12157897B2 (es)
EP (1) EP3891278A4 (es)
JP (1) JP2022510813A (es)
KR (1) KR20210098976A (es)
CN (1) CN113039270A (es)
AU (1) AU2019392554A1 (es)
BR (1) BR112021010785A2 (es)
CA (1) CA3119799A1 (es)
MX (1) MX2021006241A (es)
SG (1) SG11202105861WA (es)
WO (1) WO2020117910A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115803440A (zh) * 2020-06-02 2023-03-14 康泰伦特药物解决方案有限责任公司 用于蛋白质制造的核酸构建体

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US6455275B1 (en) 1980-02-25 2002-09-24 The Trustees Of Columbia University In The City Of New York DNA construct for producing proteinaceous materials in eucaryotic cells
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5149636A (en) 1982-03-15 1992-09-22 Trustees Of Columbia University In The City Of New York Method for introducing cloned, amplifiable genes into eucaryotic cells and for producing proteinaceous products
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US5139941A (en) 1985-10-31 1992-08-18 University Of Florida Research Foundation, Inc. AAV transduction vectors
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
WO1990003430A1 (en) 1988-09-23 1990-04-05 Cetus Corporation Cell culture medium for enhanced cell growth, culture longevity and product expression
US5225347A (en) 1989-09-25 1993-07-06 Innovir Laboratories, Inc. Therapeutic ribozyme compositions and expression vectors
US5256568A (en) * 1990-02-12 1993-10-26 Regeneron Phamaceuticals, Inc. Vectors and transformed most cells for recombinant protein production with reduced expression of selectable markers
WO1992001070A1 (en) 1990-07-09 1992-01-23 The United States Of America, As Represented By The Secretary, U.S. Department Of Commerce High efficiency packaging of mutant adeno-associated virus using amber suppressions
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US6027722A (en) 1990-10-25 2000-02-22 Nature Technology Corporation Vectors for gene transfer
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5512421A (en) 1991-02-19 1996-04-30 The Regents Of The University Of California Generation, concentration and efficient transfer of VSV-G pseudotyped retroviral vectors
DK0648271T3 (da) 1991-08-20 2003-07-21 Us Gov Health & Human Serv Adenovirusmedieret overførsel af gener til mave-/tarmkanal
AU7321294A (en) 1993-06-30 1995-01-24 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College, The Transformed eukaryotic cells, and transposon-based transformation vectors
US5677170A (en) 1994-03-02 1997-10-14 The Johns Hopkins University In vitro transposition of artificial transposons
US5843742A (en) 1994-12-16 1998-12-01 Avigen Incorporated Adeno-associated derived vector systems for gene delivery and integration into target cells
US5686120A (en) 1995-05-22 1997-11-11 Wisconsin Alumni Research Foundation Pre-mRNA processing enhancer and method for intron-independent gene expression
US6013516A (en) 1995-10-06 2000-01-11 The Salk Institute For Biological Studies Vector and method of use for nucleic acid delivery to non-dividing cells
US5965443A (en) 1996-09-09 1999-10-12 Wisconsin Alumni Research Foundation System for in vitro transposition
CA2262476C (en) * 1996-09-20 2007-05-29 Cold Spring Harbor Laboratory Viral vectors and their uses
WO1999005295A1 (en) 1997-07-25 1999-02-04 Thomas Jefferson University Composition and method for targeted integration into cells
US6136597A (en) 1997-09-18 2000-10-24 The Salk Institute For Biological Studies RNA export element
US5994136A (en) 1997-12-12 1999-11-30 Cell Genesys, Inc. Method and means for producing high titer, safe, recombinant lentivirus vectors
US20030224415A1 (en) * 2001-06-29 2003-12-04 Gala Design, Inc. Selection free growth of host cells containing multiple integrating vectors
US20040235173A1 (en) 2000-07-03 2004-11-25 Gala Design, Inc. Production of host cells containing multiple integrating vectors by serial transduction
AU2001271614B2 (en) 2000-07-03 2007-05-31 Catalent Pharma Solutions, Llc Host cells containing multiple integrating vectors
EP1613724A4 (en) * 2002-11-18 2010-09-01 Us Gov Health & Human Serv CELL LINES AND NUCLEAR ACIDIC ACIDS IN CONNECTION WITH INFECTION DISEASES
CN100429315C (zh) * 2003-03-11 2008-10-29 雪兰诺实验室有限公司 含有mcmv ie2启动子的表达载体
JP4751326B2 (ja) * 2003-09-04 2011-08-17 メダレックス インコーポレイテッド 発現ベクター
US7632509B2 (en) * 2005-07-19 2009-12-15 Biosante Pharmaceuticals, Inc. Methods to express recombinant proteins from lentiviral vectors
EP2325322A1 (en) 2009-11-23 2011-05-25 4-Antibody AG Retroviral vector particles and methods for their generation and use
US20160194660A1 (en) * 2012-12-21 2016-07-07 Merck Sharp & Dohme Corp. Expression vectors for recombinant protein production in mammalian cells
KR20170081784A (ko) * 2016-01-04 2017-07-13 한국과학기술원 Gs 유전자가 결핍된 신규한 hek293 세포주 및 상기 형질전환된 hek293 숙주세포를 이용한 목적 단백질의 생산 방법
KR20180093086A (ko) * 2016-01-06 2018-08-20 론자 리미티드 개선된 생산을 위한 단백질 분해의 억제
CN107164409B (zh) * 2017-04-17 2021-01-15 华中农业大学 犬瘟热病毒敏感细胞系slam-mdck及其构建方法和应用
CN115803440A (zh) * 2020-06-02 2023-03-14 康泰伦特药物解决方案有限责任公司 用于蛋白质制造的核酸构建体

Also Published As

Publication number Publication date
EP3891278A1 (en) 2021-10-13
US20220056476A1 (en) 2022-02-24
BR112021010785A2 (pt) 2021-11-16
JP2022510813A (ja) 2022-01-28
SG11202105861WA (en) 2021-07-29
KR20210098976A (ko) 2021-08-11
CN113039270A (zh) 2021-06-25
AU2019392554A1 (en) 2021-06-03
CA3119799A1 (en) 2020-06-11
EP3891278A4 (en) 2022-08-31
US12157897B2 (en) 2024-12-03
WO2020117910A1 (en) 2020-06-11

Similar Documents

Publication Publication Date Title
MX2023011785A (es) Metodos y composiciones para produccion de proteina de clara de huevo.
TN2017000552A1 (en) Antibody constructs for msln and cd3.
PH12017501365A1 (en) Novel promoter and uses thereof
TN2017000551A1 (en) Antibody constructs for cd70 and cd3.
SA520412669B1 (ar) تصنيع ذيفانات عصبية ناتجة عن معاودة الارتباط الجيني من المطثية الوشيقية
MX2017003847A (es) Proteinas biespecificas activables por proteasas.
PH12018501280A1 (en) Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
MY192158A (en) Anti-pd-1 antibodies and their uses
MX2023001834A (es) Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
MX2021008367A (es) Constructos de anticuerpos para cdh19 y cd3.
PH12017500022A1 (en) Carrier-antibody compositions and methods of making and using the same
MY193497A (en) Anti-myostatin antibodies and methods of use
MX2018010842A (es) Expresion mediada por el virus adeno-asociado (aav) usando un promotor y pontenciador sintetico.
MX2017007127A (es) Composiciones que comprenden polipeptidos que tienen actividad xilanasa y polipeptidos que tienen actividad arabinofuranosidasa.
TN2019000015A1 (en) Bispecific antibody-like binding proteins specifically binding to cd3 and cd123
WO2018081592A3 (en) Compositions and methods for the production of compounds
WO2016022377A3 (en) Methods for modulating the glycosylation profile of recombinant proteins using dissolved oxygen
MX2021001460A (es) Metodos y composiciones para secrecion de polipeptidos heterologos.
PH12016501689B1 (en) Tatk-cdkl5 fusion proteins, compositions, formulations, and use thereof
WO2017112847A8 (en) Improved protein expression strains
MX2021006241A (es) Vectores para la fabricacion de proteinas.
MX2021009154A (es) Selectividad eficaz de proteinas recombinantes.
WO2018081350A8 (en) SIGNAL POLYPEPTIDE FOR ENHANCED PROTEIN SECRETION
SG11201902998SA (en) PROMOTER OF Hspa5 GENE
MX2018003445A (es) Expresion de proteinas que contienen fc.